WARNING

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close [x]

Call Us Today

(410) 686-3000
m

Call Today (410) 686-3000

or fill out this form and we will get in touch with you shortly 
 

Current Trials

ALCON RTH258-C001

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular AgeRelated Macular Degeneration

Description: To demonstrate that RTH258 is not inferior to aflibercept with respect to the change in BCVA from baseline in patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration. Treatment arms: RTH258 3 mg, RTH258 6 mg and Aflibercept.

ALLERGAN CEDAR

150998-005 Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration

Description: To assess the safety and efficacy of abicipar compared with ranibizumab in patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration. Treatment arms: 2mg abicipar 8 weeks, 2mg abicipar 12 weeks and ranibizumab.

DRCR

Diabetic Retinopathy Clinical Research Network  

Protocol S: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Description: To determine if visual acuity outcomes at 2 years in eyes with PDR that receive anti-VEGF therapy with deferred PRP are non-inferior to those in eyes that received standard prompt PRP therapy. (Not enrolling)

Protocol T: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema

Description: To compare the efficacy and safety of intravitreal aflibercept, intravitreal bevacizumab and intravitreal ranibizumab when given to treat center-involved DME in eyes.

Protocol U: Short-term Evaluation of Combination Corticosteroid + Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy

Description: To assess the short-term effects of combination steroid + anti-VEGF therapy on visual acuity and retinal thickness on OCT in comparison with that of continued anti-VEGF done in eyes with persistent center-involved DME and decreased visual acuity despite previous anti-VEGF treatment.

Protocol V: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

Description: To compare the safety and efficacy of prompt focal/grid photocoagulation + deferred intravitreal anti-VEGF, observation + deferred intravitreal anti-VEGF, and prompt intravitreal anti-VEGF in eyes with central-involved DME and good visual acuity 20/25 or better.

Protocol W: Treatment for patients with severe NPDR, determined by Reading Center.

Description: Patient are treated with Eylea versus sham (observation) to determine if early treatment will slow the progression to PDR. Vision 20/25 or better. 4 year study


Protocol AA: Peripheral Diabetic Retinopathy Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening over Time

Description: To assess whether evaluation of the retinal far periphery on ultrawide-field images improves the ability to assess DR and predict rates of DR worsening over time as compared with evaluation only of the area within the 7 standard ETDRS fields.

FILLY-POT

Description: Patients with Geographic Atrophy determined by Reading Center. Randomized to one of 4 arms. Study drug Monthly; Study drug EOM; Sham Monthly; Sham EOM. 12 month study.

GENENTECH (BOULEVARD)

Description:  DME determined by Reading Center. Randomized to one of 3 arms. Lucentis q4weeks; Study drug (1.5mg) q4weeks; Study drug (6mg) q4weeks. Vision 20/40-20/320. 7 month study

GENENTECH GX29455

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy 

Description: The GX29455 Phase II is a controlled study of the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks or every 4 weeks for 24 weeks to CFI profile biomarker-positive patients with GA secondary to age-related macular degeneration (AMD). Treatment arms: lampalizumab every 2 weeks, lampalizumab every 4 weeks and sham injection.  

OHR

Description: Randomized to study drug (drops) or placebo. Patients will receive Lucentis Monthly for 1 year then PRN in year 2. Will use drops BID thoughout the study.  Vision 20/40-20/320. 2 year study

ORBIT

Ocriplasmin Research to Better Inform Treatment. (Not enrolling)

PEACHTREE 

Uveitis study. Patients with non-infectious uveitis and macular edema. Randomized to triamcinolone vs sham suprachoroidal injections at Day 0 and Week 12. Vision 20/40-20/800. 6 month study

REGENERON

Description: Study drug (2 different doses) versus Eylea.  Patients receive 3 doses then re-randomized based upon findings to possible different arm. Vision 20/40-20/320. 32 week study.

SCORE2

Standard Care vs. Corticosteroid for Retinal Vein Occlusion 2 (Not enrolling)

Description: A randomized trial designed to test whether bevacizumab is non-inferior to aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO).  Treatment arms: intravitreal aflibercept(2mg) every 4 weeks or intravitreal bevacizumab (1.25mg) every 4 weeks.

XCOVERY 201

A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea compared to prn Eylea monotherapy in neovascular AMD

Description: To evaluate the safety and efficacy of X-82 at three doses versus placebo in combination with intravitreal injection of Eylea prn for patients with wet age-related macular degeneration (AMD). Treatment arms:  X-82 50mg, 100mg, or 200 mg plus Eylea prn versus placebo plus Eylea prn.

Past Trials

Age-Related Eye Disease Study 2

Foreseehome: Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the Foreseehome Device APGS - AMD Phenotype and Genotype Study

AREDS2, Age-Related Eye Disease Study

Randomized Trial of Lutein, Zeaxanthin, and Long-Chain Omega-3 Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration

CATT

Comparison of Age-Related Macular Degeneration Treatment Trials

Novartis SPP100A2244 Study

A randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300mg once daily for diabetic macular edema

iDEAL Study

A Randomized Multi-center, Phase 2 Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic macular edema with Involvement of the Foveal Center

Ohr 002

Phase 2 study of the efficacy and safety of Squalamine Lactate Ophthalmic Solution 0.2% twice daily in subjects with neovascular age-related macular degeneration

Ohr 003

Topical Squalamine In The Treatment Of Retinal Neovascularization From Proliferative Diabetic Retinopathy (ask Dr. Elman if he wants this listed.

MERCK ALZHEIMER STUDY

OHR 1501

Phase 2 study of safety, functional and anatomical effect of Squalamine Lactate Ophthalmic Solution 0.2% administered twice daily in subjects with neovascular age-related macular degeneration

Description: The study will assess the safety of Squalamine Lactate Ophthalmic Solution 0.2% administered twice daily by subjects in combination with monthly intravitreal injections of Lucentis or Eylea.

Novartis

A Multi-center, randomized, sham-controlled, repeat-dose study to assess the safety-tolerability, serum pharmokinetics, and efficacy of intravitreal LFG316 in patients with neovascular age-related macular degeneration.

Post Treatment Foresee Home

Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular AMD

POSURDEX

A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700ug Dexamethasone Posterior Segment Delivery System Applicator System as Adjunctive Therapy to Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.

Xcovery

A Phase 1/2 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects with Neovascular Age-related Macular Degeneration

SIRIUS

Allergan SIRIUS Study 211745-001

SCORE

Standard Care vs. Corticosteroid for Retinal Vein Occlusion

VERTACLE

Multi-Center Randomized, Phase II/III Clinical Trial to Study the Effects of Preservative Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants with Neovascular Age-Related Macular Degeneration

AREDS

Age-Related Eye Disease Study

EOP 1023

A Phase IV, open label, multi-center trial of maintenance intravitreous injections of Macugen (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular Age-Related Macular Degeneration (AMD) initially treated with modality resulting in maculopathy improvement

Services
We strive to provide complete care for our patients. Learn more about all the services we provide.
Make An Appointment
We will do our best to accommodate your busy schedule. Schedule an appointment today!
Online Forms
Our patient forms are available online so they can be completed in the convenience of your own home or office.